荷兰青少年接种脑膜炎球菌C群破伤风类毒素加强疫苗后保护性抗体的长期持久性
本研究对9年前接种过单剂MenC-TT疫苗的10、12、15岁青少年加强接种MenC-TT,并在加强前及加强后1个月、1年、3年采集血样。201名(75%)受试者完成3年随访,所有受试者rSBA滴度仍≥8,98%≥128;模型估计10、12、15岁组滴度降至保护阈值以下的中位时间分别为16.3年、45.9年和约270年。
要点
- 加强接种后3年,所有受试者rSBA滴度仍≥8,98%≥128。
- 15岁组抗体滴度最高,10岁组最低。
- 模型估计10、12、15岁组降至保护阈值以下的中位时间分别为16.3年、45.9年和约270年。
核心结论
- 青少年加强接种MenC-TT后抗体水平在1年内快速下降,1至3年间缓慢下降。
- 荷兰常规青少年MenC-TT加强接种可能提供长期个体保护,并可能降低普通人群中MenC疾病复发的风险。
研究设计与样本
- 对10、12、15岁青少年(9年前接种过单剂MenC-TT)加强接种MenC-TT,在加强前及加强后1个月、1年、3年采集血样。
- 采用兔补体血清杀菌试验(rSBA)检测功能性抗体,荧光珠多重免疫分析法检测荚膜多糖和破伤风类毒素特异性抗体,纵向多水平抗体衰减模型估计长期保护。
- 原268名参与者中201名(75%)在3年后完成随访。
主要发现
- 加强后3年,所有参与者rSBA滴度仍高于保护阈值≥8,98%≥128。
- 15岁组抗体滴度最高。
- 双指数衰减模型估计,10、12、15岁组加强后rSBA滴度降至保护阈值(<8)的中位时间分别为16.3年、45.9年和约270年。
临床怎么用
- 原文结论认为,荷兰青少年常规MenC-TT加强接种可能提供长期个体保护,并可能降低普通人群中MenC疾病复发的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Due to waning immunity, infant vaccination with meningococcal serogroup C conjugated (MenCC) vaccines is insufficient to maintain long-term individual protection. Adolescent booster vaccination is thought to offer direct protection against invasive meningococcal disease (IMD) but also to reduce meningococcal carriage and transmission and in this way establish herd protection in the population. Previously, we studied antibody levels after adolescent MenCC booster vaccination. In the present study, the adolescent vaccinees were revisited after three years to determine antibody persistence and to predict long-term protection. METHODS: Meningococcal serogroup C tetanus toxoid conjugated (MenC-TT) vaccine was administered to 10-, 12- and 15-year old participants who had been primed nine years earlier with a single dose of MenC-TT vaccine. Blood samples were collected before, 1month, 1year and 3years after the adolescent booster vaccination. Functional antibody levels were measured with serum bactericidal assay using rabbit complement (rSBA). Meningococcal serogroup C polysaccharide and tetanus toxoid specific antibody levels were measured using fluorescent-bead-based multiplex immunoassay. Long-term protection was estimated using longitudinal multilevel antibody decay modeling. RESULTS: Of the original 268 participants, 201 (75%) were revisited after 3years. All participants still had an rSBA titer above the protective threshold of ⩾8 and 98% ⩾128. The 15-year-olds showed the highest antibody titers. Using a bi-exponential decay model, the median time to fall below the protection threshold (rSBA titer <8) was 16.3years, 45.9years and around 270years following the booster for the 10-, 12- and 15-year-olds, respectively. CONCLUSIONS: After a first steep decline in antibody levels in the first year after the booster, antibody levels slowly declined between one and three years post-booster. A routine MenC-TT booster vaccination for adolescents in the Netherlands will likely provide long-term individual protection and potentially reduce the risk of resurgence of MenC disease in the general population.
引用
- van Ravenhorst MB, Marinovic AB, van der Klis FR, et al. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination. Vaccine. 2016. PMID: 27817957. doi:10.1016/j.vaccine.2016.10.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。